 Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States Food and Drug Administration FDA denied the Citizen Petition filed by Clarus Therapeutics Inc. Clarus on October 2, 2019. Specifically, the FDA declined to issue product-specific guidance on oral T-ester drug products and denied without comment Clarus request regarding how the FDA should review and make approval decisions on any pending or future oral T-ester products. 